ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1375	National Cancer Institute	Html	en	Cancer Screening Overview (PDQ®)–Health Professional Version	Information about measuring the effectiveness of cancer screening tests and about weighing the strength of the evidence obtained from cancer screening research studies.	PDQ Screening 0.435302 cancer antigen 0.351044 cancer screening interventions 0.511292 advanced-stage pancreatic cancer 0.361147 cancer screening 0.938139 lung cancer screening 0.519031 new screening test 0.500274 cancer prevention 0.350991 Interval cancer events 0.364348 new screening modality 0.453389 IIIB–IV lung cancer 0.361117 prostate screening 0.417963 lung cancer rates 0.355466 prostate cancer treatment 0.3549 mammography screening 0.457867 screening program 0.415447 screening summaries 0.435473 disease-specific mortality 0.409334 cancer cases 0.346604 whole-body screening technologies 0.500642 lower cancer risk 0.359738 interval cancer rates 0.358328 colorectal cancer 0.351483 routine cancer screening 0.555956	recent screening 0.436851 false-negative screening test 0.511207 older screening modalities 0.448481 breast cancer 0.418358 cancer diagnosis 0.374736 prostate cancer screening 0.551218 actual cancer risk 0.422669 cancer screening tests 0.659235 randomized controlled trial 0.36573 prostate cancer mortality. 0.348853 false-positive screening results 0.509129 screening center 0.444606 fecal occult blood 0.356414 higher cancer risk 0.360321 cancer mortality. 0.353113 decision making 0.410621 all-cause mortality 0.362129 breast cancer overdetection 0.35093 routine screening mammographies 0.474709 randomized clinical trials 0.34952 Cancer Screening Trial 0.566983 invasive diagnostic procedures 0.355819 routine PSA screening 0.472621	CLICK HERE
1408	National Cancer Institute	Html	en	Grief, Bereavement, and Coping With Loss (PDQ®)–Health Professional Version	Expert-reviewed report about grief, bereavement, and feelings of loss in survivors of someone who has died of cancer. Grief in children is also discussed.	normal grief process 0.581221 unanticipated grief 0.551516 IPT 0.463911 depressive symptoms 0.559773 loss 0.542758 common emotional reactions 0.45155 children 0.526047 interpersonal problems 0.458662 middle phase 0.464448 Health care providers 0.455228 grief counseling exists. 0.565426 grief 0.933904 anticipatory grief 0.744484 health care professionals 0.481565 unanticipated death differs 0.464542 exposure therapy 0.455194 bereaved people 0.453892 grief experiences 0.564377 grief reactions 0.683036 minimal grief reaction—a 0.565 age range 0.479943 grief symptoms 0.544738 deceased person 0.466915 grief intensity 0.535236	necessary grieving process 0.451469 social reactions 0.450213 select grief assessment 0.557139 normal grief 0.697811 death 0.578011 grief bursts 0.548077 IPT group 0.456027 cancer experience 0.45206 grieving process 0.505158 chronic grief reactions 0.566742 complicated grief 0.62885 term anticipatory grief 0.59229 health care 0.509332 common grief reactions 0.572313 pathologic grief reactions 0.569264 normal emotional process 0.454248 bereaved persons 0.498553 severe grief reactions 0.591257 grief disorder 0.543808 actual death 0.478188 grief treatment 0.548186 bereaved persons experience 0.472239 grief experience 0.541082 stage models 0.450278	CLICK HERE
1696	National Cancer Institute	Html	en	Topics in Integrative, Alternative, and Complementary Therapies (PDQ®)–Health Professional Version	Expert-reviewed information summary that contains information on integrative, complementary, and/or alternative therapies for people with cancer.	cancer treatment 0.500109 standard treatments 0.546145 National Health Interview 0.49394 randomized controlled trials 0.478599 good manufacturing processes 0.485786 Cancer Complementary 0.466196 blood cell count 0.487384 NCI Fact Sheets 0.492301 concomitantly administered drugs 0.486833 depression management 0.497623 cancer information summary 0.503433 potentially active ingredients 0.480985 PDQ summaries 0.45939 St. John 0.975444 cancer patients 0.494368 NCI Fact 0.496884 wort 0.678406 effects 0.47211 complementary therapies 0.460635 cancer survivors 0.459401 PDQ summary section 0.501629 human immunodeficiency virus 0.480593 various metabolic enzymes 0.481932 major active constituents 0.486518 commonly treated symptoms 0.485606	Chinese medical therapies 0.495937 antidepressant therapy 0.478022 deep breathing exercises. 0.492057 Complementary medicine 0.467053 CAM therapies 0.48574 specific PDQ summary 0.501712 dietary supplements 0.496339 systemic concentrations 0.461386 alternative medicine 0.659692 herbal agent 0.488319 natural killer cell 0.486571 lower concentrations 0.45956 traditional Chinese medicine 0.494167 clinically important effect 0.485748 monoamine oxidase inhibitor 0.490216 PDQ summary 0.540549 randomized controlled trials. 0.478417 popular herbal agent 0.484348 NCI Fact Sheet 0.49194 major depressive disorder 0.543366 Alternative Medicine website 0.499408 sufficient concentrations 0.46476 milder depression 0.458918 cancer 0.510149	CLICK HERE
1999	National Cancer Institute	Html	es	Tratamiento de los astrocitomas infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los astrocitomas infantiles.	siguientes procedimientos 0.509449 células madre 0.756546 siguientes aspectos 0.541249 efectos secundarios meses 0.505608 sustancia llamada fcev 0.432048 prueba mib-1 0.42502 vía oral 0.416944 encéfalo benignos 0.476825 único tratamiento 0.445679 proteína cinasa.Los inhibidores 0.434623 glioma coroideo 0.430143 escasas ocasiones 0.429534 células t 0.452739 efectos tardíos 0.580441 estrella llamadas 0.429847 PDQ Efectos tardíos 0.459317 National Cancer Institute 0.412326 tumores benignos 0.512758 siguientes riesgos 0.412382	alto recién 0.437854 Instituto Nacional 0.422716 PDQ Tratamiento 0.437378 determinados cambios 0.429353 neurofibromatosis tipo 0.592389 tanta cantidad 0.426418 presente sección 0.412644 nuevos tipos 0.4212 siguientes casos 0.43033 sistema nervioso central 0.991625 Physician Data Query 0.447246 siguientes partes 0.443422 cuánto tumor 0.508299 cuerpo.ampliar derivación 0.416932 células cancerosas.Hay 0.455449 panel derecho 0.460499 siguientes sumarios 0.465245 vasos sanguíneos 0.616892	CLICK HERE
3597	National Cancer Institute	Html	en	MERIT Award Recipient: Laimonis A. Laimins, Ph.D.	MERIT Award Recipient: Laimonis A. Laimins, Ph.D.	productive life cycle 0.692492 anti-viral therapies 0.414992 long-term objective 0.415026 viral particles 0.475434 viral factor 0.465899 HPV types 0.533205 Viral infection 0.48447 HPV proteins functions 0.60071 proliferative lesions 0.427068 stratified epithelial cells 0.554619 E4 protein 0.416206 small DNA viruses 0.509754 development 0.367942 life cycle 0.732336 tissue culture 0.408683 cervical cancer 0.697893 anogenital cancers 0.416749 viral replication 0.470226 pathogenesis 0.323941 certain types 0.427907 late viral functions 0.551387 HPV functions 0.507234 genetic analyses 0.407346 HPV infections 0.62415 activation 0.321394	productive viral life 0.570807 blocks infection 0.430045 E5 protein 0.409072 differentiation 0.394198 HPVs 0.330868 methods 0.33537 virion assembly 0.42345 genome amplification 0.41342 human papillomaviruses 0.908593 Oncogenic Papillomaviruses 0.574563 organotypic cultures 0.4081 normal cells 0.43284 suprabasal cells 0.432461 cases 0.370169 effective anti-virals 0.431518 epithelial cells 0.561264 protein synthesis 0.412779 HPV viral proteins 0.658868 vaccine 0.388142 Additional studies 0.403147 future 0.32145 cell death pathway 0.503149 high-risk types 0.424894 grant 0.339966	CLICK HERE
3898	National Cancer Institute	Html	en	National Cancer Act of 1971	The National Cancer Act of 1971, signed into law by President Richard Nixon, established the National Cancer Institute in its current form.	local public agencies 0.263615 National Cancer Advisory 0.650054 United States Code 0.285316 presidentially appointed committee 0.280399 congress 0.267955 section 0.313878 members 0.281565 periodic public hearings 0.26114 National Advisory Cancer 0.311011 cancer research effort 0.272363 National Institutes 0.423416 President’s Cancer 0.269099 peer review groups 0.27756 new cancer program 0.274372 cancer research data 0.317718 director 0.357764 Cancer Conquest Program 0.270321 Cancer Advisory Council 0.261669 formal peer review 0.25641 National Cancer Act 0.322085 national effort 0.266101 research data bank 0.295559 programs 0.258759 new cancer centers 0.270844 National Cancer 0.961422	United States 0.352369 international cancer research 0.31865 sec. 0.262726 Advisory Cancer Council 0.296567 cancer research 0.391545 new National Cancer 0.296152 new cancer research 0.280939 cancer control activities 0.268219 national program 0.264635 National Cancer Institute 0.922231 Cancer Panel 0.285667 NCI director 0.269686 health professions personnel 0.261888 cancer research program 0.301343 comprehensive national program 0.262972 comprehensive national plan 0.253394 Health Service Act 0.445842 national cancer program 0.58313 Public Health Service 0.448514 cancer research activities 0.2733 Cancer Conquest Agency 0.262618 annual budget 0.264713 Cancer Advisory Board 0.646243 total national commitment 0.252359	CLICK HERE
4329	National Cancer Institute	Html	en	Cancer Screening	A summary of the benefits and possible harms of cancer screening tests.	time symptoms 0.320649 abnormal tissue 0.346264 False-negative test results 0.440391 screening tests 0.953871 false reassurance 0.328265 potential harms 0.743558 different cancer screening 0.573019 medical care 0.312433	people 0.200595 Early detection 0.319119 additional tests 0.299571 health problems 0.324983 doctors 0.208104 False-positive test results 0.450006 cancer 0.861445	CLICK HERE
14600	National Cancer Institute	Html	es	Tratamiento de los tumores vasculares infantiles (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores vasculares infantiles.	Natl Acad Sci 0.324634 anomalías vasculares retinianas 0.33309 hemangiomas is directly 0.365854 lesiones benignas 0.319493 Infants With Infantile 0.316042 lesiones precursoras 0.322133 frecuencia cardíaca 0.363288 cells from hemangiomas 0.365897 Denise Adams 0.34719 Ampliar Figura 0.334799 hemangiomas perioculares subcutáneos 0.383239 propranolol quizás 0.334782 Prospective study 0.315057 capillary hemangioma 0.369091 International Society 0.348608 vasculares hepáticos benignos 0.326723 tumores vasculares benignos 0.402681 Léauté-Labrèze C 0.314686 evaluación cardíaca 0.323474 angiofibromas nasofaríngeos 0.342724 síndrome phace 0.577507 angiofibroma nasofaríngeo 0.314735 anomalías renales 0.316886 Children With Infantile 0.315749 oral propranolol 0.362065	Clin Invest 0.327186 hemangiomas congénitos 0.761656 endothelial cells 0.315693 hemangiomas cutáneos 0.372477 Arch Dermatol 0.329954 Cuadro clínico 0.393896 Proc Natl Acad 0.325302 infantile hemangiomas 0.938164 With Infantile Hemangioma 0.438965 Nadolol Versus Propranolol 0.33549 vías respiratorias 0.521847 granuloma piógeno 0.329351 Vascular Anomalies Classification 0.319289 insuficiencia cardíaca transitoria 0.335633 antecedentes familiares 0.32937 hemangioma cutáneo congénito 0.383839 Complicated Vascular Anomalies 0.316136 Benigno Hemangioma 0.393265 Drolet BA 0.324986 lesiones cutáneas 0.338858 clasificación issva 0.316546 Blei F 0.314967 hemangioma epitelioide 0.552561 Hoeger P 0.315823	CLICK HERE
15632	National Cancer Institute	Html	null	NCI Grant Application Development, Submission, and Award	Learn how the six-step process of the NCI grants process works— from application development, to peer review, to post-award administration.			CLICK HERE
16844	National Cancer Institute	Html	en	Ohio State University and University of Kentucky — Optimizing RNA Nanoparticle's Size and Shape for Enhancing Cancer Targeting and Treatment	A systematic characterization of RNA nanoparticle behavior, in vitro and in vivo, to optimize its cellular delivery to triple negative breast cancer (TNBC).	optimized therapeutic systems 0.528757 varying shapes 0.305417 moieties 0.241586 endosomal escape 0.300775 RNA nanoparticle behavior 0.817424 optimum shape 0.346242 project team 0.300326 vivo delivery 0.345174 overall goal 0.318652 therapeutic components 0.373072 Jianhua Yu 0.345836 tumor regression 0.318722 Enhancing Cancer Targeting 0.687284 William Carson 0.342459 internalization/intracellular trafficking 0.315312 efficient therapeutic delivery 0.542327 surgical oncology 0.297773	delivery systems 0.312116 pharmacokinetic profiles 0.331727 Daniel Pack 0.340086 Ohio State University 0.5489 nanoparticle size 0.433341 gene therapy 0.299174 RNA nanoparticles 0.513535 negative breast cancer 0.501323 facile chemical processing 0.476016 rna nanoparticle 0.954079 Principal Investigators 0.353961 Peixuan Guo 0.400645 favorable biodistribution 0.529957 molecular / cell 0.296003 cancer immunotherapy 0.325509 systematic studies 0.315425 systematic characterization 0.33975	CLICK HERE